The addition of panitumumab (Vectibix) to FOLFIRI (an irinotecan-based combination chemotherapy) prolonged progression-free survival and overall survival compared with FOLFIRI alone as second-line therapy for metastatic colorectal cancer in patients with wild-type KRAS.